WuXi Biologics

WuXi Biologics is a global Contract Research Development and Manufacturing Organization (CRDMO) that provides open-access, integrated technology platforms for biologics drug development.

WuXi Biologics' roots date back to 2010, and began building out capabilities and facilities required for biologics discovery, development and good manufacturing practices (GMP). WuXi Biologics went public on the Hong Kong Stock Exchange in June 2017.

As of 2021, WuXi Biologics has 18 manufacturing sites including ten in China, three in the United States, two in Ireland, two in Germany, and one in Singapore.

In August 2020, WuXi Biologics was selected to become a component of the Hang Seng Index in Hong Kong.

In January 2024, WuXi Biologics' share price fell on news that the United States Congress had introduced legislation to block any federal government contracts with the company due to national security concerns. The concerns stem from allegations, denied by the company, that it has worked closely with the People's Liberation Army as a part of the Chinese Communist Party's military-civil fusion strategy. Members of the United States House Select Committee on Strategic Competition between the United States and the Chinese Communist Party subsequently called for sanctions against WuXi Biologics.